Placeholder Banner

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

January 15, 2015
Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey.

Your investment plans and budgets all include growth assumptions and market forecasts. Can you trust them? 2014 was another banner year for biotech IPOs, with 81 companies in our industry going public, an increase of nearly 90 percent over 2013.

Now we turn our attention to the year ahead and what we can expect. More blue skies or dark clouds?  M&A surpassing last year or settling down? What is the next blockbuster drug—or will policymakers and insurers halt the next blockbuster before it gets out of the gate? What will be the breakthroughs to watch in 2015 like CAR-T and CRISPR were this past year? Which therapeutic areas have been undervalued and are ready to shine?

BIO, in conjunction with Bloomberg Intelligence, invites you to answer a brief, 3-minute, industry outlook survey. Please share your expertise to tap into the “wisdom of the crowd.”

Answer our 15 questions to get your 2015 answers. Survey participants will get first access to results before the rest of the biotech community. All responses will remain anonymous. Where do your forecasts fit among your colleagues’ estimates? What research developments are they watching most closely?

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey.

Results and full analysis of their implications will be shared with attendees at the 17th annual BIO CEO & Investor Conference taking place February 9th and 10th at the Waldorf Astoria, New York City.

To register now or learn more about the BIO CEO & Investor Conference, including programming and partnering information, plus the names of more than 150 presenting companies, please visit here.

The conversation will continue on the implications of the survey’s results at the 3rd Annual State of Health Care Summit taking place on February 13th at Bloomberg’s New York headquarters.